Treatment with bevacizumab and irinotecan in patients with recurrent or refractory high grade glioma after conventional treatment.

Trial Profile

Treatment with bevacizumab and irinotecan in patients with recurrent or refractory high grade glioma after conventional treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Irinotecan (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top